Kimberly Gentile
CIK 1704186 · SVP, Clinical Operations · last filed 2026-09-17
Kimberly Gentile is a SVP, Clinical Operations who has filed 29 SEC Form 4 insider transactions across 1 company since 2017. The most recent filing, for BHVN, was dated Sep 17, 2026. Across all open-market trades the lifetime net is −$6.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions. 24 SEC filings were submitted jointly with Biohaven Pharmaceutical Holding Co Ltd.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BHVN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
234 CHURCH STREET
NEW HAVEN, CT 06510
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BHVN | SVP, Clinical Operations | 101,513 | $10.78 | $1.09M | -$6.10M | 28 | 2026-09-17 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-17 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2026-03-03 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2026-01-07 | BHVN | Mixed | +1,794 | -$19.4K | EDGAR |
| 2025-01-07 | BHVN | Mixed | +1,794 | -$75.6K | EDGAR |
| 2024-01-04 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2023-11-06 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2022-10-05 | — | Mixed | +95,969 | $18.7K | |
| 2022-10-03 | BHVN | Disp (D) | −11,653 | -$1.73M | EDGAR |
| 2022-01-07 | BHVN | Mixed | +1,950 | -$222.9K | EDGAR |
| 2021-11-26 | BHVN | Mixed | +2,012 | -$200.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.